New study tests migraine drug as attack stopper
NCT ID NCT06628921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the migraine drug eptinezumab can stop a migraine attack while it is being given through an IV. Researchers want to know how fast the headache goes away and if other bothersome symptoms also disappear. The study will include 50 adults who have migraines at least 8 days per month and are already scheduled to start eptinezumab as part of their regular care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Campus Biomedico
RECRUITINGRoma, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a numbing nose treatment stop migraine pain in its tracks?
- Can migraine meds be safe while breastfeeding? a new study investigates
- Could a symptom registry unmask hidden migraine variants?
- A migraine-blocking antibody tested in children as young as 6
- Mind over migraine: brain network may explain why some expect side effects
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?